Last updated on November 2019

Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma

Brief description of study

This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and anti-lymphoma activity of an autologous T cell product (ACTR707) in combination with rituximab in subjects with refractory or relapsed CD20+ B cell lymphoma.

Clinical Study Identifier: NCT03189836

Find a site near you

Start Over

University of Maryland

Baltimore, MD United States
  Connect »